Comparative Pharmacology
Head-to-head clinical analysis: CRESTOR versus FLUVASTATIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRESTOR versus FLUVASTATIN SODIUM.
CRESTOR vs FLUVASTATIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased hepatic LDL receptor expression and reduced plasma LDL cholesterol.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to decreased intracellular cholesterol levels and upregulation of LDL receptors.
Oral, 5-40 mg once daily. Initial dose typically 10-20 mg; max 40 mg.
20 to 80 mg orally once daily in the evening; immediate-release: 20-40 mg once daily; extended-release: 80 mg once daily.
None Documented
None Documented
The terminal elimination half-life is approximately 19 hours (range 13–20 hours). This long half-life allows once-daily dosing and provides sustained HMG-CoA reductase inhibition.
The terminal elimination half-life is 2.3 hours (range 1.4–3.1 hours). Due to its short half-life, it is dosed once daily for sustained HMG-CoA reductase inhibition; however, pharmacodynamic effects (LDL reduction) persist beyond plasma clearance.
Approximately 90% of rosuvastatin is eliminated in feces (as unchanged drug and metabolites), and about 10% is excreted in urine (mainly as unchanged drug). Biliary excretion is the primary route for elimination of metabolites.
Fluvastatin sodium is primarily eliminated via biliary/fecal excretion (approximately 90%), with renal excretion accounting for less than 6% of the administered dose.
Category C
Category D/X
Statin
Statin